Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma

John M. Kirkwood*, Lars Bastholt, Caroline Robert, Jeff Sosman, James Larkin, Peter Hersey, Mark Middleton, Mireille Cantarini, Victoria Zazulina, Karin Kemsley, Reinhard Dummer

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

239 Scopus citations

Fingerprint

Dive into the research topics of 'Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science